Mechanism of action Several modes of action have been proposed to explain the association between steroid treatment and improvement in lung function. They include an increase in surfactant synthesis2 3; enhancement of ,-adrenergic activity4; stimulation of antioxidant production2; stabilisation of cell and lysosomal membrane5; breakdown of granulocyte aggregates with improvement in the pulmonary microcirculation6 7; inhibition of prostaglandin and leukotrine synthesis8 9 ; removal of excess lung water'0; and suppression of the cytokine mediated inflammatory reaction in the lung." The latter two theories are of particular interest and may provide an explanation for the rapid changes in lung function.
Ariagno et al demonstrated a marked steroid induced reduction in lung water content in newborn mice raised in an 80% oxygen environment.'0 They showed that the decrease in lung water was due to a loss of fluid from the interstitial tissue of the lung with no reduction in the thickness of the blood-gas barrier. Sahebjami et al have also shown that steroids can accelerate the resolution of pulmonary oedema and improve alveolar volume either by increasing the rate of reabsorption or decreasing the formation of alveolar fluid exudate."2 Further support for the lung fluid theory comes from a recent study that demonstrated that diuresis occurred within 48 hours of the commencement of dexamethasone in preterm infants with BPD. 13 This diuretic phase correlated closely with the period of improved lung function.
Another plausible explanation may relate to the ability of corticosteroids to suppress the inflammatory process induced by barotrauma and oxygen toxicity. The cytokine, tumour necrosis factor-oa (TNF-x), was not present in the bronchopulmonary secretions of ventilated preterm infants until after four days of postnatal age."I Thereafter, the concentration increased progressively and the highest concentrations were found in babies with BPD who required prolonged ventilatory and oxygen support. It was of interest to note that the time course of TNF-a production correlated well with the pattern of inflammatory cell migration into the lungs. The influx of polymorphonuclear neutrophils and activated alveolar macrophages in turn triggered an inflammatory reaction leading to pulmonary fibrosis. '4 The concentrations of TNF-ax and inflammatory cells from bronchopulmonary lavage were dramatically decreased within 24 hours of starting steroid treatment." Dexamethasone decreased the synthesis of the cytokine and limited the polymorphonuclear cell and macrophage migration to the inflamed area. Hence, it has the ability to restrain the alveolar macrophage induced alveolitis and prevent the full activation of the inflammatory cascade.
Despite intensive research, the exact mechanism to explain the action of dexamethasone has not been fully delineated. As the pathogenesis of BPD is complex and multifactorial, it is likely that more than one mechanism is responsible for the acute and rapid improvement of pulmonary function seen with steroid. The overall picture appears to be that dexamethasone probably exerts its effect by reducing the tracheobronchial alveolar inflammatory response and pulmonary oedema, thereby facilitating gas exchange, airway patency, and improving lung compliance which enables successful extubation. (1) INDICATIONS Dexamethasone is only of proved value in infants who develop BPD and have difficulty in weaning from the ventilator.5-21 24 At present, there is not enough evidence to extend its recommendation to infants who are oxygen dependent but are not ventilated. Although in the latter group, a transient reduction in oxygen requirement has been demonstrated, the overall duration of oxygen dependency was not shortened. 23 24 Babies who show continuous and steady improvement or suffer a temporary setback in ventilation, especially due to sepsis, must not be hastily put on dexamethasone. It is also essential that every effort is taken to identify all treatable causes that may prevent successful weaning before any baby is commenced on steroid treatment. Factors like anaemia and metabolic derangements must be corrected; haemodynamically significant patent ductus arteriosis must be treated; sepsis should be excluded by C reactive protein and blood cultures; and plasma caffeine concentrations must be maintained well within the therapeutic range of facilitate diaphragmatic function and to prevent apnoea. Only after exclusion of all these treatable causes should dexamethasone be considered as the next option.
(2) TIMING In most studies infants were started on steroid treatment between the second and fourth week of postnatal age. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] given during that period is proved to be of value with regard to weaning from the ventilator. Interestingly, recent evidence suggests that dexamethasone given much earlier for the treatment of respiratory distress syndrome on day 1 is also effective in improving pulmonary status and facilitating extubation.25 By minimising barotrauma and oxygen induced toxicity in the initial period, steroids are potentially able to reduce the incidence of lung injury. Furthermore, we have recently demonstrated that TNF-ax in endotracheal aspirate only appears in significant quantity after day 4 of postnatal age"I and perhaps this represents the most appropriate timing for starting steroid treatment to suppress pulmonary inflammation. Another advantage of starting dexamethasone treatment on day 4 is to allow the exclusion of congenital infection, which is at times impossible to differentiate from respiratory distress syndrome. A double blind randomised study is currently underway at our institution to investigate the effect of day 4 steroid on ventilation parameters and its impact on the incidence and severity of BPD. 
40%. In the ventilated group, dexamethasone was obviously given as a rescue measure after all forms of conventional treatment had failed. All six infants responded initially with a reduction in ventilation and oxygen requirement but only four continued to show adequate improvement to permit extubation. The other two infants continued to deteriorate and required increasing ventilatory support. They eventually died because of BPD and respiratory failure. As to the unventilated, oxygen dependent group, dexamethasone was given to minimise supplemental oxygen requirement. A transient beneficial effect was observed in the first week but in most cases oxygen requirement increased as the dose of steroid was reduced. All infants in this group survived.
As this is a clinical observation, and involves only a small number of infants, it does not allow a firm conclusion to be drawn with regard to the use of a repeat course of dexamethasone. However, a 67% success rate of extubation in the ventilated group is encouraging. I have no hesitation in trying a second course of steroid when an infant remains stuck on the ventilator while all other therapeutic options have already been attempted.
The adverse effects of dexamethasone Although the side effects of corticosteroids have been extensively investigated in older children and adults, they have not been com- Hypertension secondary to sodium retention is a common problem in dexamethasone treated infants and has been reported in the majority of studies.16-18 20-22 24 31 As different criteria for the definition of significant hypertension have been used, the exact incidence remains unknown. It is reassuring, however, that in the majority of cases no treatment is required.
A lesser known side effect of corticosteroids on the heart is their potential to cause cardiac muscle hypertrophy. 35 36 Intraventricular septum and left ventricle free wall thickness were reported to be increased after two weeks' treatment by dexamethasone. 35 The hypertrophy of these structures appeared to resolve spontaneously by six weeks when the steroid was stopped. 35 No differences were noted in the ejection fraction. 35 This phenomenon appears to be completely reversible.
There was also a report suggesting that dexamethasone could induce sinus bradycardia in preterm infants.20 This claim was, however, unsubstantiated by other workers. ( 
4) RESPIRATORY COMPLICATIONS
It seems almost contradictory to suggest that dexamethasone given to ventilator dependent premature infants for improving their pulmonary function can give rise to pulmonary complications. An increase in the incidence of pulmonary air leaks soon after the start of dexamethasone treatment was probably related to a sudden improvement of pulmonary compliance, leading to overdistension and rupture. '8 This complication is potentially avoidable by vigilant monitoring so that as compliance improves, ventilation pressure can be decreased appropriately. I recently encountered three cases of gastroduodenal perforation in preterm infants treated with dexamethasone. 37 The overall incidence is in the region of 2-3%. It was almost always preceded by haematemesis or melaena. In all cases, prompt resuscitation with abdominal paracentesis and early surgical intervention were performed in order to ensure a favourable outcome. Isolated cases of renal calcification have been identified in premature infants who receive dexamethasone and frusemide treatment38; both are known to be calciuric drugs.
As none of the randomised trials looked specifically for its pattern of occurrence or incidence, the true frequency is not known.
One can only presume that infants treated with dexamethasone, especially in conjunction with frusemide, are at an increased risk of developing renal calcification. No data are available on their long term renal function.
(7) MUSCULOSKELETAL COMPLICATIONS Steroid myopathy, with or without muscle wasting, affects principally the proximal musculature of the limbs. A substantial increase in plasma amino acid concentration39 and a simultaneous increase in urinary excretion of 3-methylhistidine,40 soon after dexamethasone was started, was most likely to be due to endogenous myofibrillar protein catabolism. Clinical myopathy in preterm neonates is difficult, if not impossible, to detect and no such case has been reported in the literature so far. Although I have undoubtedly seen poor muscle bulk in babies who have received dexamethasone, I have not encountered any baby who developed frank muscle weakness or paralysis.
Osteopenia and bony fracture are sometimes seen in preterm infants. It is difficult to evaluate the role of steroids in these events as other confounding factors such as immobilisation secondary to the use of muscle relaxants, nutritional rickets, catabolism induced by stress or sepsis, and the use of calciuric drugs may all, in part, be responsible for the poor mineralisation of the bony matrix. neutrophilia is due to a shift of neutrophils from the marginating pool to the circulating pool, an acceleration of the release of mature neutrophils from the bone marrow, and a reduction of the egress of neutrophils from blood to inflammatory sites. Other haematological effects include an enhancement of erythropoiesis, thrombocytosis, monocytopenia, lymphopenia, and eosinopenia.
The anti-inflammatory and immunosuppressive effects of corticosteroids have been extensively investigated. The complexity of the immune system in association with wide variation in response depending on the animal species42 43 gives rise to much controversy in assessing the effect of steroids on the human immune function. The current view is that this category of drug has the capability to divert the trafficking, circulation, and availability of inflammatory cell populations to the inflammatory site and possibly in therapeutic dose modify their functions in vivo.42 43 Interestingly, the anti-inflammatory potency of a particular steroid has little influence on its immunosuppressive effect. 44 affected by dexamethasone and are not reliable predictors of infection but plasma C reactive protein concentration is unaffected and remains a good indicator for monitoring neonatal sepsis.
In the past few years, even the less common and infrequent side effects of steroids such as gastrointestinal perforation are increasingly being recognised.37 Therefore, neonatal clinicians must be equipped with the knowledge and must be prepared to encounter even the lesser known and rare complications of dexamethasone treatment.
Perhaps, in future, the use of more specific treatments such as monoclonal antibody to TNF-x and inhaled corticosteroids will emerge to be better treatment for BPD, with fewer side effects. Until more is known about the safety and beneficial effects of systemic steroids in this group of patients, in particular their influence on long term neurodevelopmental and pulmonary outcome, indiscriminate use should be prohibited. I believe the prudent course is to restrict their use to ventilator dependent infants with moderate to severe BPD. 
